Диссертация (1141269), страница 15
Текст из файла (страница 15)
17, No. 11, 2003. pp. 1157–1162.100. Wang D., Jiang K., Yang S., Qin F., Lu X., Li F. Determination of nifedipine inhuman plasma by ultra performance liquid chromatography-tandem mass112spectrometry and its application in a pharmacokinetic study // Journal ofChromatography B, Vol. 879, No. 20, 2011. pp. 1827–1832.101. Roman M., Ström L., Tell H., Josefsson M. Liquid chromatography/time-offlight mass spectrometry analysis of postmortem blood samples for targetedtoxicological screening // Analytical and Bioanalytical Chemistry, Vol. 405,No. 12, 2013. pp.
4107-4125.102. Castro A., Gergov M., Östman P., Ojanperä I., Pelander A. Combined drugscreening and confirmation by liquid chromatography time-of-flight massspectrometry with reverse database search // Analytical and BioanalyticalChemistry, Vol. 403, No. 5, 2012.
pp. 1265-1278.103. Tahboub Y.R. Chromatographic behavior of co-eluted plasma compounds andeffect on screening of drugs by APCI-LC–MS(/MS): Applications to selectedcardiovascular drugs // Journal of Pharmaceutical Analysis, Vol. 4, No.
6, 2014.pp. 384–391.104. Suzuki O., Watanabe K. Drugs and Poisons in Humans: A Handbook ofPractical Analysis. Springer Science & Business Media, 2006. 325-328 pp.105. Руководство по экспертизе лекарственных средств под ред. проф. А. Н.Миронова. Том I. / М.: Гриф и К, 2013.106. Guidance for Industry: Bioanalytical method validation. U.S.
Department ofHealth and Human Services, Food and Drug Administration, Center for DrugEvolution and Research (CDER). U.S. Government Printing Office:Washington, DC, 2001.107. Guideline on bioanalytical method validation. European Medicines Agency.Committee for medicinal products for human use: London, 2011..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
